HALOZYME THERAPEUTICS, INC. Proceeds and Excess Tax Benefit from Share-based Compensation
HALOZYME THERAPEUTICS, INC. (HALO) reported Proceeds and Excess Tax Benefit from Share-based Compensation of $0 for the 3-month period ending 2017-03-31, per its 10-Q filed 2017-05-09.
Discontinued › Notes › Compensation Related Costs
us-gaap:ProceedsAndExcessTaxBenefitFromSharebasedCompensation · last filed 2017-05-09
- HALOZYME THERAPEUTICS, INC. proceeds and excess tax benefit from share-based compensation for the quarter ending 2017-03-31 was $0.00.
- HALOZYME THERAPEUTICS, INC. proceeds and excess tax benefit from share-based compensation for the quarter ending 2016-09-30 was $0.00.
- HALOZYME THERAPEUTICS, INC. proceeds and excess tax benefit from share-based compensation for the quarter ending 2016-06-30 was $0.00.
- HALOZYME THERAPEUTICS, INC. proceeds and excess tax benefit from share-based compensation for the quarter ending 2016-03-31 was $0.00.
| Period end | Proceeds and Excess Tax Benefit from Share-based Compensation 3 month | Proceeds and Excess Tax Benefit from Share-based Compensation 6 month | Proceeds and Excess Tax Benefit from Share-based Compensation 9 month |
|---|---|---|---|
| 2017-03-31 | $0.00 10-Q · filed 2017-05-09 | ||
| 2016-09-30 | $0.00 10-Q · filed 2016-11-07 | $0.00 derived: sum of 2 quarters · filed 2016-11-07 | $0.00 10-Q · filed 2016-11-07 |
| 2016-06-30 | $0.00 10-Q · filed 2016-08-09 | $0.00 10-Q · filed 2016-08-09 | |
| 2016-03-31 | $0.00 10-Q · filed 2016-05-09 | ||
| 2015-09-30 | $0.00 10-Q · filed 2015-11-09 | $0.00 derived: sum of 2 quarters · filed 2015-11-09 | $0.00 10-Q · filed 2015-11-09 |
| 2015-06-30 | $0.00 10-Q · filed 2015-08-10 | $0.00 10-Q · filed 2015-08-10 | |
| 2015-03-31 | $0.00 10-Q · filed 2015-05-11 | ||
| 2014-09-30 | $0.00 10-Q · filed 2014-11-10 | $0.00 derived: sum of 2 quarters · filed 2014-11-10 | $0.00 10-Q · filed 2014-11-10 |
| 2014-06-30 | $0.00 10-Q · filed 2014-08-11 | $0.00 10-Q · filed 2014-08-11 | |
| 2014-03-31 | $0.00 10-Q · filed 2014-05-12 | ||
| 2013-09-30 | $0.00 10-Q · filed 2013-11-08 | $0.00 derived: sum of 2 quarters · filed 2013-11-08 | $0.00 10-Q · filed 2013-11-08 |
| 2013-06-30 | $0.00 10-Q · filed 2013-08-07 | $0.00 10-Q · filed 2013-08-07 | |
| 2013-03-31 | $0.00 10-Q · filed 2013-05-08 | ||
| 2012-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-08 | $0.00 10-Q · filed 2012-11-08 | |
| 2012-06-30 | $0.00 10-Q · filed 2012-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |